Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on November 4, 2019. The report covers events occurring in early November 2019, specifically referencing financial results for the quarter ended September 30, 2019, and a new executive employment agreement dated November 6, 2019.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in a press release (Exhibit 99.1) but are not detailed within the body of this 8-K document.
Material Changes and Executive Compensation
The primary material event reported is the appointment of Regina Marek as Vice President of Finance, Principal Financial Officer, and Principal Accounting Officer. Key terms of her employment agreement include:
- Base Salary: $270,000 annually.
- Target Bonus: 35% of annual base salary.
- Retention Bonus: A previously disclosed cash retention payment of $120,000, payable at the end of the second quarter of fiscal year 2020, contingent on continued employment.
- Stock Options (New Grant): 44,300 shares granted on November 4, 2019, with a 10-year term. Vesting begins February 15, 2020 (25%), followed by monthly installments over 36 months.
- Stock Options (Prior Grant): 153,300 shares approved in May 2019, vesting 50% on June 30, 2020, and 50% on June 30, 2021.
- Severance:
- Standard termination (without cause/good reason): 12 months base salary, 12 months medical benefits, and 12-month acceleration of time-based vesting.
- Change in Control termination (within 15 months): 1.5x (base salary + target bonus), 18 months medical benefits, and full acceleration of time-based vesting.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, outlook statements, or risk factors beyond the standard legal disclaimers regarding the employment agreement. The document notes that the financial results for the quarter ended September 30, 2019, were announced on November 7, 2019, via a press release furnished as an exhibit.
Investor Verification Checklist
- Verify the actual Q3 2019 financial results (revenue, cash burn, net loss) in the press release attached as Exhibit 99.1, as they are not listed in this summary.
- Confirm the total dilution impact of the new 44,300 share option grant and the existing 153,300 share grant on outstanding shares.
- Review the full text of the employment agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Monitor the company's cash position to ensure it can sustain the $120,000 retention bonus and ongoing executive compensation obligations.